Bioengineering the infarcted heart by applying bio-inspired materials

Journal of Cardiovascular Translational Research

Volumn 4, Issue 5, 2011, Pages 559-574

  Ruvinov, Emil ^a   Harel Adar, Tamar ^a   Cohen, Smadar ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Affinity binding; Alginate; Inflammation; Macrophages; Myocardial infarction; PS presenting liposomes

Indexed keywords

ALGINIC ACID; BIOMATERIAL; GLYCOSAMINOGLYCAN; HEPARIN BINDING PROTEIN; INTERLEUKIN 10; LIPOSOME; PHOSPHATIDYLSERINE; SCATTER FACTOR; SOMATOMEDIN C; TISSUE SCAFFOLD; TRANSFORMING GROWTH FACTOR BETA;

ACUTE HEART INFARCTION; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BINDING AFFINITY; BIOCOMPATIBILITY; BIOMEDICAL TECHNOLOGY ASSESSMENT; CYTOKINE RELEASE; EXTRACELLULAR MATRIX; HEART DEVELOPMENT; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART VENTRICLE REMODELING; HUMAN; HYDROGEL; IMMUNOMODULATION; MACROPHAGE ACTIVATION; MUSCLE REGENERATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SCAR FORMATION; STEM CELL TRANSPLANTATION; THERAPY EFFECT; TISSUE ENGINEERING; TISSUE REPAIR;

ALGINATES; ANIMALS; BIOCOMPATIBLE MATERIALS; BIOENGINEERING; DISEASE MODELS, ANIMAL; DRUG CARRIERS; EXTRACELLULAR MATRIX PROTEINS; GLUCURONIC ACID; HEXURONIC ACIDS; INJECTIONS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPOSOMES; MACROPHAGES; MICE; MYOCARDIAL INFARCTION; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHATIDYLSERINES; RATS; REGENERATION; REGENERATIVE MEDICINE; TIME FACTORS; TISSUE SCAFFOLDS; VENTRICULAR REMODELING;

RATTUS;

EID: 81855183235     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-011-9288-9     Document Type: Review

References (110)

1. World Health Organization. The atlas of heart disease and stroke. http://www.who.int/cardiovascular-diseases/resources/atlas/en/
2. Lloyd-Jones, D., Adams, R. J., Brown, T. M., et al. (2010). Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation, 121(7), e46-e215.
3. McMurray, J. J. (2010). Clinical practice. Systolic heart failure. The New England Journal of Medicine, 362(3), 228-238.
4. Bergmann, O., Bhardwaj, R. D., Bernard, S., Zdunek, S., Barnabe-Heider, F., Walsh, S., et al. (2009). Evidence for cardiomyocyte renewal in humans. Science, 324(5923), 98-102.
5. Kajstura, J., Urbanek, K., Perl, S., Hosoda, T., Zheng, H., Ogorek, B., et al. (2010). Cardiomyogenesis in the adult human heart. Circulation Research, 107(2), 305-315.
6. Hsieh, P. C., Segers, V. F., Davis, M. E.,MacGillivray, C., Gannon, J., Molkentin, J. D., et al. (2007). Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nature Medicine, 13(8), 970-974. (Pubitemid 47222045)
7. Parmacek, M. S., & Epstein, J. A. (2009). Cardiomyocyte renewal. New England Journal of Medicine, 361(1), 86-88.
8. Porrello, E. R., Mahmoud, A. I., Simpson, E., Hill, J. A., Richardson, J. A., Olson, E. N., et al. (2011). Transient regenerative potential of the neonatal mouse heart. Science, 331(6020), 1078-1080.
9. Jopling, C., Sleep, E., Raya, M., Marti, M., Raya, A., & Belmonte, J. C. (2010). Zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation. Nature, 464 (7288), 606-609.
10. Novoyatleva, T., Diehl, F., van Amerongen, M. J., Patra, C., Ferrazzi, F., Bellazzi, R., et al. (2010). TWEAK is a positive regulator of cardiomyocyte proliferation. Cardiovascular Research, 85(4), 681-690.
11. Bersell, K., Arab, S., Haring, B., & Kuhn, B. (2009). Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell, 138(2), 257-270.
12. Hassink, R. J., Pasumarthi, K. B., Nakajima, H., Rubart, M., Soonpaa, M. H., de la Riviere, A. B., et al. (2008). Cardiomyocyte cell cycle activation improves cardiac function after myocardial infarction. Cardiovascular Research, 78(1), 18-25. (Pubitemid 351430951)
13. Campa, V. M., Gutierrez-Lanza, R., Cerignoli, F., Diaz-Trelles, R., Nelson, B., Tsuji, T., et al. (2008). Notch activates cell cycle reentry and progression in quiescent cardiomyocytes. The Journal of Cell Biology, 183(1), 129-141.
14. Ahuja, P., Sdek, P., & MacLellan, W. R. (2007). Cardiac myocyte cell cycle control in development, disease, and regeneration. Physiological Reviews, 87(2), 521-544. (Pubitemid 47086282)
15. Bollini, S., Smart, N., & Riley, P. R. (2011). Resident cardiac progenitor cells: at the heart of regeneration. Journal of Molecular and Cellular Cardiology, 50, 296-303. doi:10.1016/ j.yjmcc.2010.07.006.
16. Ruvinov, E., Dvir, T., Leor, J., & Cohen, S. (2008). Myocardial repair: From salvage to tissue reconstruction. Expert Review of Cardiovascular Therapy, 6(5), 669-686.
17. Abbate, A., Bussani, R., Amin, M. S., Vetrovec, G. W., & Baldi, A. (2006). Acute myocardial infarction and heart failure: Role of apoptosis. The International Journal of Biochemistry & Cell Biology, 38(11), 1834-1840. (Pubitemid 44425247)
18. Garg, S., Narula, J., & Chandrashekhar, Y. (2005). Apoptosis and heart failure: Clinical relevance and therapeutic target. Journal of Molecular and Cellular Cardiology, 38(1), 73-79. (Pubitemid 40038653)
19. Nian, M., Lee, P., Khaper, N., & Liu, P. (2004). Inflammatory cytokines and postmyocardial infarction remodeling. Circulation Research, 94(12), 1543-1553. (Pubitemid 38856961)
20. Frangogiannis, N. G., Smith, C. W., & Entman, M. L. (2002). The inflammatory response in myocardial infarction. Cardiovascular Research, 53(1), 31-47. (Pubitemid 34020764)
21. Leask, A. (2007). TGFbeta, cardiac fibroblasts, and the fibrotic response. Cardiovascular Research, 74(2), 207-212. (Pubitemid 46533834)
22. Vanhoutte, D., Schellings, M., Pinto, Y., & Heymans, S. (2006). Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovascular Research, 69(3), 604-613. (Pubitemid 43139724)
23. Renault, M. A., & Losordo, D. W. (2007). Therapeutic myocardial angiogenesis. Microvascular Research, 74(2-3), 159-171. (Pubitemid 350051028)
24. Tomanek, R. J., Zheng, W., & Yue, X. (2004). Growth factor activation in myocardial vascularization: Therapeutic implications. Molecular and Cellular Biochemistry, 264(1-2), 3-11. (Pubitemid 39366100)
25. Zampetaki, A., Kirton, J. P., & Xu, Q. (2008). Vascular repair by endothelial progenitor cells. Cardiovascular Research, 78(3), 413-421. (Pubitemid 351769775)
26. Menasche, P. (2011). Cardiac cell therapy: Lessons from clinical trials. Journal of Molecular and Cellular Cardiology, 50, 258-265. doi:10.1016/j.yjmcc. 2010.06.010.
27. Segers, V. F., & Lee, R. T. (2008). Stem-cell therapy for cardiac disease. Nature, 451(7181), 937-942. (Pubitemid 351301749)
28. Chavakis, E., Koyanagi, M., & Dimmeler, S. (2010). Enhancing the outcome of cell therapy for cardiac repair: progress from bench to bedside and back. Circulation, 121(2), 325-335.
29. Hansson, E. M., Lindsay, M. E., & Chien, K. R. (2009). Regeneration next: toward heart stem cell therapeutics. Cell Stem Cell, 5(4), 364-377.
30. Dimmeler, S., Burchfield, J., & Zeiher, A. M. (2008). Cell-based therapy of myocardial infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(2), 208-216. (Pubitemid 351161191)
31. Maltais, S., Tremblay, J. P., Perrault, L. P., & Ly, H. Q. (2010). The paracrine effect: pivotal mechanism in cell-based cardiac repair. Journal of Cardiovascular Translational Research, 3(6), 652-662.
32. Mirotsou, M., Jayawardena, T. M., Schmeckpeper, J., Gnecchi, M., & Dzau, V. J. (2011). Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. Journal of Molecular and Cellular Cardiology, 50, 280-289. doi:10.1016/j. yjmcc.2010.08.005.
33. Gnecchi, M., Zhang, Z., Ni, A., & Dzau, V. J. (2008). Paracrine mechanisms in adult stem cell signaling and therapy. Circulation Research, 103(11), 1204-1219.
34. Laflamme, M. A., Zbinden, S., Epstein, S. E., & Murry, C. E. (2007). Cell-based therapy for myocardial ischemia and infarction: pathophysiological mechanisms. Annual Review of Pathology, 2, 307-339. (Pubitemid 46448068)
35. Beohar, N., Rapp, J., Pandya, S., & Losordo, D. W. (2010). Rebuilding the damaged heart the potential of cytokines and growth factors in the treatment of ischemic heart disease. Journal of the American College of Cardiology, 56(16), 1287-1297.
36. Vandervelde, S., van Luyn, M. J., Tio, R. A., & Harmsen, M. C. (2005). Signaling factors in stem cell-mediated repair of infarcted myocardium. Journal of Molecular and Cellular Cardiology, 39(2), 363-376. (Pubitemid 40995026)
37. Hausenloy, D. J., & Yellon, D. M. (2009). Cardioprotective growth factors. Cardiovascular Research, 83(2), 179-194.
38. Zohlnhofer, D., Dibra, A., Koppara, T., de Waha, A., Ripa, R. S., Kastrup, J., et al. (2008). Stem cell mobilization by granulocyte colony-stimulating factor for myocardial recovery after acute myocardial infarction: a meta-analysis. Journal of the American College of Cardiology, 51(15), 1429-1437. (Pubitemid 351470028)
39. Abdel-Latif, A., Bolli, R., Zuba-Surma, E. K., Tleyjeh, I. M., Hornung, C. A., & Dawn, B. (2008). Granulocyte colonystimulating factor therapy for cardiac repair after acute myocardial infarction: A systematic review and meta-analysis of randomized controlled trials. American Heart Journal, 156(2), 216-226.
40. Lee, T. M., Chen, C. C., & Chang, N. C. (2009). Granulocyte colony-stimulating factor increases sympathetic reinnervation and the arrhythmogenic response to programmed electrical stimulation after myocardial infarction in rats. The American Journal of Physiology, 297(2), H512-H522.
41. Christman, K. L., & Lee, R. J. (2006). Biomaterials for the treatment of myocardial infarction. Journal of the American College of Cardiology, 48(5), 907-913. (Pubitemid 44292446)
42. Nelson, D. M., Ma, Z., Fujimoto, K. L., Hashizume, R., & Wagner, W. R. (2011). Intra-myocardial biomaterial injection therapy in the treatment of heart failure: Materials, outcomes and challenges. Acta Biomaterialia, 7(1), 1-15.
43. Miyagawa, S., Roth, M., Saito, A., Sawa, Y., & Kostin, S. (2011). Tissue-engineered cardiac constructs for cardiac repair. The Annals of Thoracic Surgery, 91(1), 320-329.
44. Vunjak-Novakovic, G., Tandon, N., Godier, A., Maidhof, R., Marsano, A., Martens, T. P., et al. (2010). Challenges in cardiac tissue engineering. Tissue Engineering. Part B, Reviews, 16(2), 169-187.
45. Jugdutt, B. I. (2003). Ventricular remodeling after infarction and the extracellular collagen matrix: When is enough enough? Circulation, 108(11), 1395-1403. (Pubitemid 37174420)
46. Spinale, F. G. (2007). Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiological Reviews, 87(4), 1285-1342. (Pubitemid 350041472)
47. Iraqi, W., Rossignol, P., Angioi, M., Fay, R., Nuee, J., Ketelslegers, J. M., et al. (2009). Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) Study. Circulation, 119(18), 2471-2479.
48. Akhyari, P., Kamiya, H., Haverich, A., Karck, M., & Lichtenberg, A. (2008). Myocardial tissue engineering: The extracellular matrix. European Journal of Cardio-Thoracic Surgery, 34(2), 229-241.
49. Dobaczewski, M., Gonzalez-Quesada, C., & Frangogiannis, N. G. (2010). The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. Journal of Molecular and Cellular Cardiology, 48 (3), 504-511.
50. Landa, N., Miller, L., Feinberg, M. S., Holbova, R., Shachar, M., Freeman, I., et al. (2008). Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation, 117(11), 1388-1396. (Pubitemid 351506386)
51. Leor, J., Tuvia, S., Guetta, V., Manczur, F., Castel, D.,Willenz, U., et al. (2009). Intracoronary injection of in situ forming alginate hydrogel reverses left ventricular remodeling after myocardial infarction in Swine. Journal of the American College of Cardiology, 54(11), 1014-1023.
52. Dai, W., Wold, L. E., Dow, J. S., & Kloner, R. A. (2005). Thickening of the infarcted wall by collagen injection improves left ventricular function in rats: A novel approach to preserve cardiac function after myocardial infarction. Journal of the American College of Cardiology, 46(4), 714-719. (Pubitemid 41132703)
53. Christman, K. L., Fok, H. H., Sievers, R. E., Fang, Q., & Lee, R. J. (2004). Fibrin glue alone and skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial infarction. Tissue Engineering, 10(3-4), 403-409. (Pubitemid 38580261)
54. Christman, K. L., Vardanian, A. J., Fang, Q., Sievers, R. E., Fok, H. H., & Lee, R. J. (2004). Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. Journal of the American College of Cardiology, 44(3), 654-660. (Pubitemid 39089073)
55. Masuda, S., Shimizu, T., Yamato, M., & Okano, T. (2008). Cell sheet engineering for heart tissue repair. Advanced Drug Delivery Reviews, 60(2), 277-285. (Pubitemid 350236404)
56. Shimizu, T., Yamato, M., Kikuchi, A., & Okano, T. (2003). Cell sheet engineering for myocardial tissue reconstruction. Biomaterials, 24(13), 2309-2316. (Pubitemid 36434050)
57. Wang, T., Wu, D. Q., Jiang, X. J., Zhang, X. Z., Li, X. Y., Zhang, J. F., et al. (2009). Novel thermosensitive hydrogel injection inhibits post-infarct ventricle remodelling. European Journal of Heart Failure, 11(1), 14-19.
58. Yu, J., Christman, K. L., Chin, E., Sievers, R. E., Saeed, M., & Lee, R. J. (2009). Restoration of left ventricular geometry and improvement of left ventricular function in a rodent model of chronic ischemic cardiomyopathy. The Journal of Thoracic and Cardiovascular Surgery, 137(1), 180-187.
59. Mukherjee, R., Zavadzkas, J. A., Saunders, S. M., McLean, J. E., Jeffords, L. B., Beck, C., et al. (2008). Targeted myocardial microinjections of a biocomposite material reduces infarct expansion in pigs. The Annals of Thoracic Surgery, 86(4), 1268-1276.
60. Ifkovits, J. L., Tous, E., Minakawa, M., Morita, M., Robb, J. D., Koomalsingh, K. J., et al. (2010). Injectable hydrogel properties influence infarct expansion and extent of postinfarction left ventricular remodeling in an ovine model. Proceedings of the National Academy of Sciences of the United States of America, 107(25), 11507-11512.
61. Wall, S. T., Walker, J. C., Healy, K. E., Ratcliffe, M. B., & Guccione, J. M. (2006). Theoretical impact of the injection of material into the myocardium: A finite element model simulation. Circulation, 114(24), 2627-2635. (Pubitemid 44967346)
62. Gaudette, G. R., & Cohen, I. S. (2006). Cardiac regeneration: materials can improve the passive properties of myocardium, but cell therapy must do more. Circulation, 114(24), 2575-2577. (Pubitemid 44967339)
63. Davis, M. E., Hsieh, P. C., Grodzinsky, A. J., & Lee, R. T. (2005). Custom design of the cardiac microenvironment with biomaterials. Circulation Research, 97(1), 8-15. (Pubitemid 40982317)
64. Freeman, I., Kedem, A., & Cohen, S. (2008). The effect of sulfation of alginate hydrogels on the specific binding and controlled release of heparin-binding proteins. Biomaterials, 29 (22), 3260-3268.
65. Freeman, I., & Cohen, S. (2009). The influence of the sequential delivery of angiogenic factors from affinity-binding alginate scaffolds on vascularization. Biomaterials, 30(11), 2122-2131.
66. Shriver, Z., Liu, D., & Sasisekharan, R. (2002). Emerging views of heparan sulfate glycosaminoglycan structure/activity relationships modulating dynamic biological functions. European Journal of Heart Failure, 12(2), 71-77. (Pubitemid 34145266)
67. Dvir, T., Kedem, A., Ruvinov, E., Levy, O., Freeman, I., Landa, N., et al. (2009). Prevascularization of cardiac patch on the omentum improves its therapeutic outcome. Proceedings of the National Academy of Sciences of the United States of America, 106(35), 14990-14995.
68. Conti, E., Carrozza, C., Capoluongo, E., Volpe, M., Crea, F., Zuppi, C., et al. (2004). Insulin-like growth factor-1 as a vascular protective factor. Circulation, 110, 2260-2265. (Pubitemid 39372511)
69. Nakamura, T., Mizuno, S., Matsumoto, K., Sawa, Y., & Matsuda, H. (2000). Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. Journal of Clinical Investigation, 106(12), 1511-1519. (Pubitemid 32038589)
70. Ruvinov, E., Leor, J., & Cohen, S. (2011). The promotion of myocardial repair by the sequential delivery of IGF-1 and HGF from an injectable alginate biomaterial in a model of acute myocardial infarction. Biomaterials, 32(2), 565-578.
71. Suleiman, M. S., Singh, R. J., & Stewart, C. E. (2007). Apoptosis and the cardiac action of insulin-like growth factor I. Pharmacology & Therapeutics, 114(3), 278-294. (Pubitemid 46843252)
72. Li, Q., Li, B., Wang, X., Leri, A., Jana, K. P., Liu, Y., et al. (1997). Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. Journal of Clinical Investigation, 100(8), 1991-1999. (Pubitemid 27459352)
73. Webster, K. A. (2007). Programmed death as a therapeutic target to reduce myocardial infarction. Trends in Pharmacological Sciences, 28(9), 492-499. (Pubitemid 47368699)
74. Tomita, N., Morishita, R., Taniyama, Y., Koike, H., Aoki, M., Shimizu, H., et al. (2003). Angiogenic property of hepatocyte growth factor is dependent on upregulation of essential transcription factor for angiogenesis, ets-1. Circulation, 107(10), 1411-1417. (Pubitemid 36350741)
75. Nakamura, T., Matsumoto, K., Mizuno, S., Sawa, Y., & Matsuda, H. (2005). Hepatocyte growth factor prevents tissue fibrosis, remodeling, and dysfunction in cardiomyopathic hamster hearts. American Journal of Physiology, 288(5), H2131-H2139. (Pubitemid 40604097)
76. Wang, Y., Ahmad, N., Wani, M. A., & Ashraf, M. (2004). Hepatocyte growth factor prevents ventricular remodeling and dysfunction in mice via Akt pathway and angiogenesis. Journal of Molecular and Cellular Cardiology, 37(5), 1041-1052. (Pubitemid 39446829)
77. Frantz, S., Bauersachs, J., & Ertl, G. (2009). Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovascular Research, 81(3), 474-481.
78. Ruvinov, E., Leor, J., & Cohen, S. (2010). The effects of controlled HGF delivery from an affinity-binding alginate biomaterial on angiogenesis and blood perfusion in a hindlimb ischemia model. Biomaterials, 31(16), 4573-4582.
79. Segers, V. F., & Lee, R. T. (2007). Local delivery of proteins and the use of self-assembling peptides. Drug Discovery Today, 12 (13-14), 561-568. (Pubitemid 47031660)
80. Hsieh, P. C., Davis, M. E., Gannon, J., MacGillivray, C., & Lee, R. T. (2006). Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers. Journal of Clinical Investigation, 116(1), 237-248. (Pubitemid 43121809)
81. Davis, M. E., Hsieh, P. C., Takahashi, T., Song, Q., Zhang, S., Kamm, R. D., et al. (2006). Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proceedings of the National Academy of Sciences of the United States of America, 103(21), 8155-8160. (Pubitemid 43801068)
82. Segers, V. F., Tokunou, T., Higgins, L. J., MacGillivray, C., Gannon, J., & Lee, R. T. (2007). Local delivery of proteaseresistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation, 116(15), 1683-1692. (Pubitemid 47537842)
83. Richardson, T. P., Peters, M. C., Ennett, A. B., & Mooney, D. J. (2001). Polymeric system for dual growth factor delivery. Nature Biotechnology, 19(11), 1029-1034. (Pubitemid 33041886)
84. Lu, H., Xu, X., Zhang, M., Cao, R., Brakenhielm, E., Li, C., et al. (2007). Combinatorial protein therapy of angiogenic and arteriogenic factors remarkably improves collaterogenesis and cardiac function in pigs. Proceedings of the National Academy of Sciences of the United States of America, 104(29), 12140-12145. (Pubitemid 47185643)
85. Hao, X., Silva, E. A., Mansson-Broberg, A., Grinnemo, K. H., Siddiqui, A. J., Dellgren, G., et al. (2007). Angiogenic effects of sequential release of VEGF-A(165) and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovascular Research, 75(1), 178-185. (Pubitemid 46876668)
86. Lambert, J. M., Lopez, E. F., & Lindsey, M. L. (2008). Macrophage roles following myocardial infarction. International Journal of Cardiology, 130(2), 147-158.
87. Nahrendorf, M., Swirski, F. K., Aikawa, E., Stangenberg, L., Wurdinger, T., Figueiredo, J. L., et al. (2007). The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. Journal of Clinical Immunology, 204(12), 3037-3047. (Pubitemid 350179569)
88. Troidl, C., Mollmann, H., Nef, H.,Masseli, F., Voss, S., Szardien, S., et al. (2009). Classically and alternatively activated macrophages contribute to tissue remodelling after myocardial infarction. Journal of Cellular and Molecular Medicine, 13(9B), 3485-3496.
89. Torre-Amione, G., Anker, S. D., Bourge, R. C., Colucci, W. S., Greenberg, B. H., Hildebrandt, P., et al. (2008). Results of a nonspecific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet, 371(9608), 228-236.
90. Leor, J., Rozen, L., Zuloff-Shani, A., Feinberg,M. S., Amsalem, Y., Barbash, I. M., et al. (2006). Ex vivo activated human macrophages improve healing, remodeling, and function of the infarcted heart. Circulation, 114(1 Suppl), I94-I100. (Pubitemid 44297135)
91. Fürnrohr, B. G., Sheriff, A., Munoz, L., von Briesen, H., Urbonaviciute, V., Neubert, K., et al. (2005). Signals, receptors, and cytokines involved in the immunomodulatory and antiinflammatory properties of apoptotic cells. Signal Transduction, 5(6), 356-365. (Pubitemid 43048644)
92. Bose, J., Gruber, A. D., Helming, L., Schiebe, S., Wegener, I., Hafner, M., et al. (2004). The phosphatidylserine receptor has essential functions during embryogenesis but not in apoptotic cell removal. Journal of Biology, 3(4), 15.
93. Fadok, V. A., Voelker, D. R., Campbell, P. A., Cohen, J. J., Bratton, D. L., & Henson, P. M. (1992). Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. Journal of Immunology, 148(7), 2207-2216.
94. Huynh, M. L., Fadok, V. A., & Henson, P. M. (2002). Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. Journal of Clinical Investigation, 109(1), 41-50. (Pubitemid 34052540)
95. Thum, T., Bauersachs, J., Poole-Wilson, P. A., Volk, H. D., & Anker, S. D. (2005). The dying stem cell hypothesis: immune modulation as a novel mechanism for progenitor cell therapy in cardiac muscle. Journal of the American College of Cardiology, 46(10), 1799-1802. (Pubitemid 41579799)
96. Harel-Adar, T., Ben Mordechai, T., Amsalem, Y., Feinberg, M. S., Leor, J., & Cohen, S. (2011). Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair. Proceedings of the National Academy of Sciences of the United States of America, 108(5), 1827-1832.
97. van der Meer, P., Lipsic, E., Henning, R. H., Boddeus, K., van der Velden, J., Voors, A. A., et al. (2005). Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. Journal of the American College of Cardiology, 46(1), 125-133. (Pubitemid 40905140)
98. Parsa, C. J., Matsumoto, A., Kim, J., Riel, R. U., Pascal, L. S., Walton, G. B., et al. (2003). A novel protective effect of erythropoietin in the infarcted heart. Journal of Clinical Investigation, 112(7), 999-1007. (Pubitemid 38056315)
99. Torella, D., Rota, M., Nurzinska, D., Musso, E., Monsen, A., Shiraishi, I., et al. (2004). Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth factor-1 overexpression. Circulation Research, 94, 514-524. (Pubitemid 38326287)
100. Liao, S., Porter, D., Scott, A., Newman, G., Doetschman, T., & Schultz Jel, J. (2007). The cardioprotective effect of the low molecular weight isoform of fibroblast growth factor-2: The role of JNK signaling. Journal of Molecular and Cellular Cardiology, 42 (1), 106-120. (Pubitemid 44958632)
101. Bougioukas, I., Didilis, V., Ypsilantis, P., Giatromanolaki, A., Sivridis, E., Lialiaris, T., et al. (2007). Intramyocardial injection of low-dose basic fibroblast growth factor or vascular endothelial growth factor induces angiogenesis in the infarcted rabbit myocardium. Cardiovascular Pathology, 16(2), 63-68. (Pubitemid 46274403)
102. Harada, M., Qin, Y., Takano, H., Minamino, T., Zou, Y., Toko, H., et al. (2005). G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nature Medicine, 11(3), 305-311. (Pubitemid 40460559)
103. Takano, H., Ueda, K., Hasegawa, H., & Komuro, I. (2007). GCSF therapy for acute myocardial infarction. Trends in Pharmacological Sciences, 28(10), 512-517. (Pubitemid 47488506)
104. Kondo, I., Ohmori, K., Oshita, A., Takeuchi, H., Fuke, S., Shinomiya, K., et al. (2004). Treatment of acute myocardial infarction by hepatocyte growth factor gene transfer: the first demonstration of myocardial transfer of a "functional" gene using ultrasonic microbubble destruction. Journal of the American College of Cardiology, 44(3), 644-653. (Pubitemid 39078194)
105. Jayasankar, V., Woo, Y. J., Bish, L. T., Pirolli, T. J., Chatterjee, S., Berry, M. F., et al. (2003). Gene transfer of hepatocyte growth factor attenuates postinfarction heart failure. Circulation, 108 (Suppl 1), II230-II236. (Pubitemid 37099960)
106. Hsieh, P. C.H.,MacGillivray, C., Gannon, J., Cruz, F. U.,&Lee, R. T. (2006). Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation, 114, 637-644. (Pubitemid 44252305)
107. Hiasa,K., Ishibashi,M.,Ohtani,K., Inoue, S., Zhao,Q.,Kitamoto, S., et al. (2004). Gene transfer of stromal cell-derived factor-1alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization. Circulation, 109(20), 2454-2461. (Pubitemid 38679567)
108. Hu, X., Dai, S., Wu, W. J., Tan, W., Zhu, X., Mu, J., et al. (2007). Stromal cell derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injury: role of the cardiac stromal cell derived factor-1 alpha CXCR4 axis. Circulation, 116(6), 654-663. (Pubitemid 47356350)
109. Ferrarini, M., Arsic, N., Recchia, F. A., Zentilin, L., Zacchigna, S., Xu, X., et al. (2006). Adeno-associated virus-mediated transduction of VEGF165 improves cardiac tissue viability and functional recovery after permanent coronary occlusion in conscious dogs. Circulation Research, 98(7), 954-961.
110. Vera Janavel, G., Crottogini, A., Cabeza Meckert, P., Cuniberti, L., Mele, A., Papouchado, M., et al. (2006). Plasmid-mediated VEGF gene transfer induces cardiomyogenesis and reduces myocardial infarct size in sheep. Gene Therapy, 13(15), 1133-1142. (Pubitemid 44101363)